Form 4: Tessa Cigler Acquires 10,000 Atossa Therapeutics RSUs

Tessa Cigler, a Director at Atossa Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on May 12, 2026, which are set to vest one year later.

Summary

• Tessa Cigler, a Director of Atossa Therapeutics, Inc., received a grant of 10,000 Restricted Stock Units (RSUs) on May 12, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs are scheduled to vest on the first anniversary of the grant date, May 12, 2027.
• Following this transaction, Ms. Cigler directly beneficially owns 10,000 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation grant to a director rather than a significant financial event or strategic shift for the company.

Positives

• Grant of 10,000 RSUs to a Director, indicating potential alignment of management and shareholder interests.
• The RSUs vest over one year, providing a retention incentive for the Director.

Risks

• The value of the RSUs is tied to the future performance of Atossa Therapeutics' common stock.
• Vesting is contingent on continued service, meaning the Director could forfeit the RSUs if employment ceases before the vesting date.

Future Outlook

The RSUs granted will vest on May 12, 2027, at which point they will convert into shares of common stock, subject to the terms of the grant agreement.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units (RSUs) to directors is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key leadership, aligning their financial interests with long-term company performance.

Stakeholder Impact

• Shareholders: The grant of RSUs represents a form of compensation that dilutes existing share ownership slightly upon vesting. However, it also aims to align director incentives with shareholder value creation.
• Employees: This filing does not directly impact employees, but it is part of the broader compensation structure for executive and director levels.
• Management: The grant serves as an incentive for the Director to remain with the company and contribute to its success.

Next Steps

• The RSUs will vest on May 12, 2027.
• Upon vesting, the RSUs will convert into shares of Atossa Therapeutics, Inc. common stock.

Key Dates

Keywords

Atossa Therapeutics, Form 4, Tessa Cigler, Restricted Stock Units, RSU Grant, Director Compensation, Insider Transaction, SEC Filing